Robert Hindes, MD, is the former vice president of clinical development for Pharmasset, located in Princeton, New Jersey. As a pharmaceutical consultant, Robert Hindes, MD, currently works on the development of treatments for influenza and hepatitis C.
Recently, a study in the New England Journal of Medicine found that two oral treatments in combination were effective in treating hepatitis C. Daclatasvir and sofosbuvir in combination achieved high SVR rates even in patients who previously failed other HCV treatments. The new findings suggest that nearly all individuals with chronic HCV infection can be treated, with a high likelihood of cure. In the US, only about 5 percent of the 3.2 million infected Americans have been cured.
Approved by the FDA on December 6, 2013, sofosbuvir is used with existing peginterferon and ribavirin for genotype 1 of the disease. Daclatasvir is not yet approved by the FDA but an application for approval has been submitted. Developers of the medications believe that Interferon will no longer be needed for effective treatment of HCV infection.